Literature DB >> 11559816

Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.

M Zheng1, S Deshpande, S Lee, N Ferrara, B T Rouse.   

Abstract

This report analyzes the role of vascular endothelial growth factor (VEGF)-induced angiogenesis in the immunoinflammatory lesion stromal keratitis induced by ocular infection with herpes simplex virus (HSV). Our results show that infection with replication-competent, but not mutant, viruses results in the expression of VEGF mRNA and protein in the cornea. This a rapid event, with VEGF mRNA detectable by 12 h postinfection (p.i.) and proteins detectable by 24 h p.i. VEGF production occurred both in the virus-infected corneal epithelium and in the underlying stroma, in which viral antigens were undetectable. In the stroma, VEGF was produced by inflammatory cells; these initially were predominantly polymorphonuclear leukocytes (PMN), but at later time points both PMN and macrophage-like cells were VEGF producers. In the epithelium, the major site of VEGF-expressing cells in early infection, the infected cells themselves were usually negative for VEGF. Similarly, in vitro infection studies indicated that the cells which produced VEGF were not those which expressed virus. Attesting to the possible role of VEGF-induced angiogenesis in the pathogenesis of herpetic stromal keratitis were experiments showing that VEGF inhibition with mFlt(1-3)-immunoglobulin G diminished angiogenesis and the severity of lesions after HSV infection. These observations are the first to evaluate VEGF-induced angiogenesis in the pathogenesis of stromal keratitis. Our results indicate that the control of angiogenesis represents a useful adjunct to therapy of herpetic ocular disease, an important cause of human blindness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559816      PMCID: PMC114555          DOI: 10.1128/JVI.75.20.9828-9835.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  Clinical applications of angiogenic growth factors and their inhibitors.

Authors:  N Ferrara; K Alitalo
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection.

Authors:  G Elliott; P O'Hare
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 3.  Vascular-specific growth factors and blood vessel formation.

Authors:  G D Yancopoulos; S Davis; N W Gale; J S Rudge; S J Wiegand; J Holash
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

4.  Herpes simplex virus-specific T cells infiltrate the cornea of patients with herpetic stromal keratitis: no evidence for autoreactive T cells.

Authors:  G M Verjans; L Remeijer; C M Mooy; A D Osterhaus
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-08       Impact factor: 4.799

5.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

Authors:  H P Gerber; J Kowalski; D Sherman; D A Eberhard; N Ferrara
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

6.  KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells.

Authors:  J T Stine; C Wood; M Hill; A Epp; C J Raport; V L Schweickart; Y Endo; T Sasaki; G Simmons; C Boshoff; P Clapham; Y Chang; P Moore; P W Gray; D Chantry
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

7.  Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea.

Authors:  J L Edelman; M R Castro; Y Wen
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-05       Impact factor: 4.799

8.  VEGF is major stimulator in model of choroidal neovascularization.

Authors:  N Kwak; N Okamoto; J M Wood; P A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-09       Impact factor: 4.799

9.  Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.

Authors:  R Sun; S F Lin; K Staskus; L Gradoville; E Grogan; A Haase; G Miller
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  HSV-1-mediated modulation of cytokine gene expression in a permissive cell line: selective upregulation of IL-6 gene expression.

Authors:  S Kanangat; J S Babu; D M Knipe; B T Rouse
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

View more
  66 in total

1.  Suppression of transcription factor early growth response 1 reduces herpes simplex virus 1-induced corneal disease in mice.

Authors:  Hui-Wen Yao; Shih-Heng Chen; Ching Li; Yuk-Ying Tung; Shun-Hua Chen
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

2.  Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1.

Authors:  Naveen K Rajasagi; Pradeep B J Reddy; Amol Suryawanshi; Sachin Mulik; Per Gjorstrup; Barry T Rouse
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

3.  Herpes simplex virus type 1 induction of chemokine production is unrelated to viral load in the cornea but not in the nervous system.

Authors:  Daniel J J Carr; Iain L Campbell
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

4.  Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.

Authors:  Bumseok Kim; Qingquan Tang; Partha S Biswas; Jun Xu; Raymond M Schiffelers; Frank Y Xie; Aslam M Ansari; Puthupparampil V Scaria; Martin C Woodle; Patrick Lu; Barry T Rouse
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 5.  Potential function of miRNAs in herpetic stromal keratitis.

Authors:  Sachin Mulik; Siddheshvar Bhela; Barry T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

6.  Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo.

Authors:  Patric Lundberg; Paula Welander; Xiao Han; Edouard Cantin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 8.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

9.  Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis.

Authors:  Sherrie J Divito; Robert L Hendricks
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

10.  Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization.

Authors:  Yanhui Bai; Weiqun Wang; Guangli Sun; Mingchang Zhang; Jingmin Dong
Journal:  Cell Prolif       Date:  2016-09-14       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.